NCT07113262View on ClinicalTrials.gov

A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Thyroid Eye Disease
Interventions
DRUG

IBI311

Teprotumumab N01 injection (code name IBI311)

DRUG

Placebo

Placebo

Trial Locations (1)

110801

The First Affiliated Hospital of Medical University, Shenyang

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT07113262 - A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease | Biotech Hunter | Biotech Hunter